Indications for Use:

The drug Sitagliptin PSK is indicated for use in adults aged 18 years and older with type 2 diabetes mellitus as monotherapy (treatment with a single drug) and in combination therapy (in combination with other medicinal products).

Monotherapy

The drug Sitagliptin PSK is indicated as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes mellitus.

Combination therapy

Combination therapy with metformin

Sitagliptin PSK in combination with metformin is indicated in adults with type 2 diabetes mellitus to improve blood sugar control as initial therapy or when diet and exercise in combination with monotherapy with one of the listed drugs does not result in adequate blood sugar control.

Combination therapy with sulfonylurea derivatives

Sitagliptin PSK in combination with sulfonylurea derivatives is indicated in patients with type 2 diabetes mellitus to improve blood sugar control when diet and exercise in combination with monotherapy with one of the listed drugs do not lead to adequate blood sugar control.

Combination therapy with PPAR-γ agonists

Sitagliptin PSK in combination with PPAR-γ agonists (thiazolidinediones) is indicated in patients with type 2 diabetes mellitus to improve blood sugar control when diet and exercise in combination with monotherapy with one of the listed drugs do not lead to adequate blood sugar control.

Combination therapy with metformin and sulfonylurea derivatives

Sitagliptin PSK in combination with metformin and sulfonylurea derivatives is indicated in patients with type 2 diabetes mellitus to improve blood sugar control when diet and exercise in combination with treatment with two of the listed drugs do not lead to adequate blood sugar control.

Combination therapy with metformin and PPAR-γ agonists

Sitagliptin PSK in combination with metformin and PPAR-γ agonists (thiazolidinediones) is indicated in patients with type 2 diabetes mellitus to improve blood sugar control when diet and exercise in combination with treatment with two of the listed drugs do not lead to adequate blood sugar control.

Combination therapy with insulin

Sitagliptin PSK is indicated in patients with type 2 diabetes mellitus as an adjunct to insulin (with or without metformin) when diet, exercise and a stable dose of insulin do not result in adequate blood sugar control.

This product is included in the Essential Drug List (EDL).

Prescription Status: Rx only.

CONTRAINDICATIONS APPLY. PLEASE CONSULT A SPECIALIST BEFORE USE.

For the full version of the medical instruction for Sitagliptin PSK (Sitagliptin) film-coated tablets, 25 mg, 50 mg, 100 mg, please visit the open access website at https://grls.rosminzdrav.ru/Default.aspx